Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.

Lydia KoiVerena BittoCorina WeiseLisa MöbiusAnnett LingeSteffen LöckAla YarominaMaría José BessoChiara ValentiniManuel PfeiferJens OvergaardDaniel ZipsIna KurthMechthild KrauseMichael Baumann

Published in: Journal of translational medicine (2023)

Nimorazole combined with RCTx improved local tumor control in some but not in all HNSCC xenografts. We identified prognostic biomarkers with the potential for translation to patients with HNSCC.

Keyphrases

clinical trial
open label
study protocol
randomized controlled trial
risk assessment
double blind
human health
placebo controlled